FROST RADAR™: Artificial Intelligence for Drug Discovery in the Pharmaceutical Industry, 2020

FROST RADAR™: Artificial Intelligence for Drug Discovery in the Pharmaceutical Industry, 2020

Benchmarking Future Growth Potential

RELEASE DATE
05-May-2020
REGION
North America
Research Code: K409-01-00-00-00
SKU: HC03288-GL-MR_24354

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC03288-GL-MR_24354

$4,950.00

$3,712.50 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16% in 2011 to almost 11% in 2018. Frost & Sullivan research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniques to address the understanding around targets and leads are inefficient. The increasing volume and veracity of clinical and research data compels traditional providers to leverage converging technologies such as artificial intelligence (AI), machine learning, natural language processing, and advanced analytics to shift from static to dynamic and adaptive data management practices. The ecosystem for supporting this growth has matured: several technology start-ups and large commercial vendors have already started delivering the impact through their products and solutions catering to drug discovery. While the benefits over the next 2 to 3 years are expected to be achieved through improved drug pipelines and faster clinical approval of new molecules, beyond that companies that integrate AI solutions will see significant impact on efficiency, cost savings and commercial success depending on their business goals.

Frost & Sullivan analysis shows that the AI impact over the pharma value chain can more than double what is achievable using traditional analytics and capture between 2% and 3% of the industry revenue, amounting to more than $50 billion in potential annual impact. This Frost Radar™ recognizes the participants that are at the forefront of developing and employing the tools. This is an industry-first benchmarking study that provides an introduction to the ecosystem and recognizes the pioneering companies.

The Frost Radar reveals the market positioning of companies in an industry using their Growth and Innovation scores as highlighted in the Frost Radar methodology. The document presents competitive profiles on each of the companies in the Frost Radar based on their strengths, opportunities, and a small discussion on their positioning. Frost & Sullivan analyzes hundreds of companies in the industry and benchmarks them across 10 criteria on the Frost Radar, where the leading companies in the industry are then positioned. Industry leaders on both the Growth and Innovation indices are recognized as best practice recipients.

Author: Amol Dilip Jadhav

Table of Contents

Strategic Imperative

Strategic Imperative (continued)

AI for Drug Discovery Market Segmentation

Growth Environment

Growth Environment (continued)

Frost Radar™

Frost Radar™

Frost Radar™

Frost Radar™

ACURASTEM, INC.

ACURASTEM, INC. (continued)

AI THERAPEUTICS

AI THERAPEUTICS (continued)

ATOMWISE

ATOMWISE (continued)

BenevolentAI

BenevolentAI (continued)

BERG

BERG (continued)

BIOVISTA INC.

BIOVISTA INC. (continued)

COTINGA PHARMACEUTICALS INC.

COTINGA PHARMACEUTICALS INC. (continued)

EVAXION BIOTECH

EVAXION BIOTECH (continued)

EXSCIENTIA LTD.

EXSCIENTIA LTD. (continued)

GRITSTONE ONCOLOGY, INC.

GRITSTONE ONCOLOGY, INC. (continued)

HEALX

HEALX (continued)

INSILICO MEDICINE

INSILICO MEDICINE (continued)

LANTERN PHARMA, INC.

LANTERN PHARMA, INC. (continued)

PHARNEXT

PHARNEXT (continued)

RECURSION PHARMACEUTICALS

RECURSION PHARMACEUTICALS (continued)

twoXAR

twoXAR (continued)

Strategic Insights

SIGNIFICANCE OF BEING ON THE FROST Radar™

FROST Radar™ EMPOWERS THE CEO’S GROWTH TEAM

FROST Radar™ EMPOWERS INVESTORS

FROST Radar™ EMPOWERS CUSTOMERS

FROST Radar™ EMPOWERS THE BOARD OF DIRECTORS

FROST Radar™: BENCHMARKING FUTURE GROWTH POTENTIAL

FROST Radar™: BENCHMARKING FUTURE GROWTH POTENTIAL

FROST Radar™: BENCHMARKING FUTURE GROWTH POTENTIAL

Legal Disclaimer

Related Research
Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16Percentage in 2011 to almost 11Percentage in 2018. Frost & Sullivan research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniques to address the understanding around targets and leads are inefficient. The increasing volume and veracity of clinical and research data compels traditional providers to leverage converging technologies such as artificial intelligence (AI), machine learning, natural language processing, and advanced analytics to shift from static to dynamic and adaptive data management practices. The ecosystem for supporting this growth has matured: several technology start-ups and large commercial vendors have already started delivering the impact through their products and solutions catering to drug discovery. While the benefits over the next 2 to 3 years are expected to be achieved through improved drug pipelines and faster clinical approval of new molecules, beyond that companies that integrate AI solutions will see significant impact on efficiency, cost savings and commercial success depending on their business goals. Frost & Sullivan analysis shows that the AI impact over the pharma value chain can more than double what is achievable using traditional analytics and capture between 2Percentage and 3Percentage of the industry revenue, amounting to more than $50 billion in potential annual impact. This Frost Radar™ recognizes the participants that are at the forefront of developing and employing the tools. This is an industry-first benchmarking study that provides an introduction to the ecosystem and recognizes the pioneering companies. The Frost Radar reveals the market positioning of companies in an industry using their Growth and Innovation scores as highlighted in the Frost Radar methodology. The document presents competitive profiles on each of the companies in the Frost Radar based on their strengths, opportunities, and a small discussion on their positioning. Frost & Sullivan analyzes hundreds of companies in the industry and benchmarks them across 10 criteria on the Frost Radar, where the leading companies in the industry are then positioned. Industry leaders on both the Growth and Innovation indices are recognized as best practice recipients. Author: Amol Dilip Jadhav
More Information
No Index No
Podcast No
Author Amol Dilip Jadhav
Industries Healthcare
WIP Number K409-01-00-00-00
Is Prebook No
GPS Codes 9564-B1,9575-B1,9600-B1,9612-B1,9562-B1,9571-B1,9573-B1,99BC-B1,99C1-B1,99C6-B1,9568-B1,9611-B1,9627-B1